July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Fluocinolone acetonide for persisting diabetic macular edema in routine clinical practice in the US. Long-term follow up.
Author Affiliations & Notes
  • Ana M Suelves
    Midwest Retina, Columbus, Ohio, United States
  • Dominic Buzzacco
    Midwest Retina, Columbus, Ohio, United States
    Ohio State University, Columbus, Ohio, United States
  • Louis Chorich III
    Midwest Retina, Columbus, Ohio, United States
    Ohio State University, Columbus, Ohio, United States
  • Sugat Patel
    Midwest Retina, Columbus, Ohio, United States
  • Footnotes
    Commercial Relationships   Ana Suelves, None; Dominic Buzzacco, None; Louis Chorich III, None; Sugat Patel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4819. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ana M Suelves, Dominic Buzzacco, Louis Chorich III, Sugat Patel; Fluocinolone acetonide for persisting diabetic macular edema in routine clinical practice in the US. Long-term follow up.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4819.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although intravitreal anti-vascular endothelial growth factor injections are considered the mainstay of diabetic macular edema (DME), some diabetic patients have a refractory DME despite multiple treatments. It poses a management challenge to retina specialists and an emotional burden for patients and their families. We performed a retrospective, observational, clinical study to analyze results of patients with persistent DME that received an intravitreal fluocinolone acetonide (FA).

Methods : A retrospective review was performed on 12 patients (16 eyes) with persistent DME treated with a FA implant and followed at least 12 months. The main outcome measures were: central retinal thickness (CRT) and best-corrected visual acuity (BCVA) before and after treatment. Information collected included demographic, clinical characteristics and treatments before and after FA implant.

Results : The mean age was 72.8 ± 7.9 years (range 60-92 years). At baseline, five patients (5 eyes) had a prior history of pars plana vitrectomy and all patients were pseudophakic. Eleven out of 12 patients had type 2 diabetes. Initial central retinal thickness (CRT) was 443.0±142 microns (mean ± standard deviation). At the end of follow up, mean CRT improved significantly in all patients to 280.0±97.1 microns (p=0.0001). The mean logMAR BCVA improved from 0.66 ± 0.37 to 0.41± 0.18 (p=0.0017). Only one patient required glaucoma medications to control intraocular pressure. Six patients (7 eyes) did not require any other treatment after the implantation of FA.

Conclusions : Fluocinolone acetonide is effective and safe in persistent DME. It provided long-term stability of DME in half of the patients in our cohort and reduced the treatment burden in the rest of our patients. This study provides further evidence that combination therapy may provide a good outcome among eyes with persistent DME following anti-VEGF therapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×